Trinayan Kashyap
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Trinayan Kashyap has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Boris Klebanov
Karyopharm Therapeutics Inc., Newton, MA 02459, USA
2 shared publicationsChristian Argueta
Karyopharm Therapeutics Inc., Newton, MA 02459, USA
2 shared publicationsMichael Kauffman
Karyopharm Therapeutics Inc., Newton, MA 02459, USA
2 shared publicationsSharon Shacham
Karyopharm Therapeutics Inc., Newton, MA 02459, USA
2 shared publicationsWilliam Senapedis
Karyopharm Therapeutics Inc., Newton, MA 02459, USA
2 shared publicationsYosef Landesman
Karyopharm Therapeutics Inc., Newton, MA 02459, USA
2 shared publications
Latest Publications
- Open Access
- 9 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4071
Focusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma
Background: The remarkable efficacy of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T) has had a significant impact on treatment strategies for relapsed/refractory multiple myeloma (RRMM). However, response durability remains a concern, necessitating the optimization of CAR-T procedures. Therapies preceding CAR-T therapy are crucial for disease control and preserving T-cell fitness. Methods: This review summarizes the evidence supporting the potential of selinexor-based regimens as holding or bridging therapy with preclinical research, demonstrating selinexor’s ability to foster an anti-inflammatory tumor microenvironment. Results: Selinexor enhances CD8+ T-lymphocyte and NK cell activation, re-polarizes macrophages, and inhibits immunosuppressive cells. Bone marrow samples from patients in clinical studies show that selinexor increases CD8 and granzyme B expression in T-cells. Selinexor also disrupts NK cell inhibition, enhances anti-tumor activity, and reduces pro-inflammatory cytokines. Selinexor may upregulate BCMA expression and increase myeloma cell immunogenicity. Real-world data suggests selinexor as bridging therapy does not compromise CAR-T outcomes and may even improve them. Conclusions: Overall, the evidence indicates selinexor’s potential to optimize CAR-T outcomes, warranting further investigation as a holding or bridging therapy for CAR-T.
- 9 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4071
Open AccessFocusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma
Background: The remarkable efficacy of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T) has had a significant impact on treatment strategies for relapsed/refractory multiple myeloma (RRMM). However, response durability remains a concern, necessitating the optimization of CAR-T procedures. Therapies preceding CAR-T therapy are crucial for disease control and preserving T-cell fitness. Methods: This review summarizes the evidence supporting the potential of selinexor-based regimens as holding or bridging therapy with preclinical research, demonstrating selinexor’s ability to foster an anti-inflammatory tumor microenvironment. Results: Selinexor enhances CD8+ T-lymphocyte and NK cell activation, re-polarizes macrophages, and inhibits immunosuppressive cells. Bone marrow samples from patients in clinical studies show that selinexor increases CD8 and granzyme B expression in T-cells. Selinexor also disrupts NK cell inhibition, enhances anti-tumor activity, and reduces pro-inflammatory cytokines. Selinexor may upregulate BCMA expression and increase myeloma cell immunogenicity. Real-world data suggests selinexor as bridging therapy does not compromise CAR-T outcomes and may even improve them. Conclusions: Overall, the evidence indicates selinexor’s potential to optimize CAR-T outcomes, warranting further investigation as a holding or bridging therapy for CAR-T.
- Open Access
- 20 July 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (56) , 30773-30786
Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
- 20 July 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (56) , 30773-30786
Open AccessSelinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
- Open Access
- 4 October 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (48) , 78883-78895
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
- 4 October 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (48) , 78883-78895
Open AccessSelinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death